**Abstract**

**Background:** The Phospholipase gene polymorphism is one factor that may influence the treatment outcome of depression. In this trial, the subjects divided into two groups, based on whether they had the PLA2 gene or Non-PLA2 gene, and then underwent treatment with mirtazapine. The purpose of the trial was to determine if the treatment outcome differed between the two groups.

**Methods:** Patients fulfilled the criteria for major depression of the Structured Clinical Interview for the DSM-5 recruited from the psychiatric outpatient clinic at a teaching hospital in southern Taiwan. Chromosomes from the white blood cellular nucleus of venous blood were withdrawn to undergo polymerase chain reaction (PCR). MAOA gene promoters larger than or equal to 4kb were considered long forms, and those smaller than or equal to 3.5kb were regarded as short forms. All patients administered the antidepressant mirtazapine. Both before and after treatment, weekly evaluations using the Hamilton\'s Depression Rating Scale (HDRS) were made, for a total of four times.

**Results:** 70 volunteers were enrolled and 56 subjects of them completed at least the second evaluation (28 males, 42 females), with 33 in the PLA2 group, and 37 in the Non-PLA2 group. 39 subjects completed the third evaluation, 34 completed the fourth. 14 subjects who completed the first evaluation only withdrew from the trial; this group included 9 subjects with the PLA2 group and 5 with the Non-PLA2 form. The post-treatment HDRS evaluation scores were lower than previous evaluations, but not reach statistical significance (p\>0.05). The HDRS scores for subjects who had taken a higher dose were comparatively higher, and reached statistical significance (z=2.17, p=0.03).

**Conclusion:** There was no difference in mirtazapine treatment outcomes between subjects with PLA2 and Non-PLA2 gene. Whether or not this was due to the side effects of the treatment is worthy of further investigation.
